Peter Doshi, Postdoctoral Fellow in Comparative Effectiveness Research, Johns Hopkins University Medical School, US, talks about “Accuracy, Completeness, and Transparency: lessons from Tamiflu experience”
Roche pharmaceuticals, the manufacturer of Tamiflu, has refused for 3 years to release key data from their Tamiflu research trial that “justifies” its use in influenza to the prestigious Cochrane Review. What are they trying to hide? Why has the FDA, CDC, and WHO endorsed using Tamiflu within the first 48 hours of symptoms of the flu when the data shows it only shortens symptoms of influenza by 1/2 to 1 day? There is no data showing that it lowers the risk for developing pneumonia or of mortality.
WHO recommends that countries stockpile this drug in case there is a pandemic from influenza that causes severe morbidity and mortality. It was recommended for the Swine flu in 2009-10 when there wasn’t even a usual number of deaths from the flu. For more information please visit www.doctorsaputo.com